Viking Therapeutics Catapults 121% As Weight-Loss Drug Beats Out Lilly's Zepbound

Viking Therapeutics Catapults 121% As Weight-Loss Drug Beats Out Lilly's Zepbound · Investor's Business Daily
ALLISON GATLIN and ED CARSON
3 min read

In This Article:

A weight-loss drug from Viking topped Lilly's Zepbound in a midstage study Tuesday. Viking stock more than doubled, while Lilly shares fell.

Recommended Stories